Related Experiment Videos
Oral methotrexate therapy for multiple superficial bladder carcinomata
Cancer Treatment Reports
|January 1, 1981
Abstract:
Patients with frequently recurring multiple class T1 bladder carcinomata have been treated with methotrexate (MTX) given as 50 mg in syrup every week. In 16 of 17 patients the frequency and number of tumor recurrences have been reduced. Measurement of MTX levels in the urine confirms that this dose of drug yields concentrations that are thought to be cytotoxic for at least 24 hours.
Insights
Weekly methotrexate (MTX) syrup effectively reduced tumor recurrence in patients with bladder cancer. This treatment achieved cytotoxic drug levels, offering a promising option for managing frequent bladder carcinoma recurrences.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Bladder cancer, specifically multiple class T1 carcinomata, frequently recurs in patients.
- Managing recurrent bladder tumors requires effective and tolerable treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of weekly oral methotrexate (MTX) in reducing tumor recurrence in patients with frequently recurring T1 bladder carcinomata.
- To confirm that the administered dose of MTX achieves cytotoxic concentrations in urine.
Main Methods:
- Patients received 50 mg of methotrexate (MTX) in syrup orally once per week.
- Tumor recurrence frequency and number were monitored.
- Methotrexate (MTX) levels were measured in urine samples to assess drug concentration.
Main Results:
- 16 out of 17 patients experienced a reduction in the frequency and number of tumor recurrences.
- Urine methotrexate (MTX) level measurements indicated cytotoxic concentrations for at least 24 hours post-administration.
Conclusions:
- Weekly oral methotrexate (MTX) is an effective treatment for reducing recurrence in patients with T1 bladder carcinomata.
- The 50 mg weekly dose of MTX achieves therapeutic drug levels, supporting its use in managing recurrent bladder cancer.